Lisozima

Il lisozima trova frequente indicazione per le sue capacità batteriolitiche e per l’attivazione dell’immunità naturale, di cui è un costituente. È documentato il suo ruolo nella resistenza alle flogosi batteriche e virali e la sua carenza è spesso associata a fragilità degli epiteli aerodigestivi superiori e alla frequenza ed intensità di recidive. Anche se non ha una rilevante efficacia antitumorale diretta, può agire attivando macrofagi e cellule immunitarie e l’immunogenecità delle popolazioni neoplastiche. Attraverso la lisi di cellule batteriche e virali, può liberare molecole ad attività immunitaria e antitumorale. L’azione del lisozima si estende alla flora patogena protozoaria, raggiungendo un ampio spettro terapeutico esteso alle patologie gastrointestinali e del cavo orale. Potenzia decisamente l’effetto antibatterico degli antibiotici, che a seconda delle condizioni può sostituire o integrare, limitando notevolmente il deficit immunitario spesso associato alla patologia neoplastica e aggravato dai trattamenti chemioterapici. La sua assenza di tossicità, in quanto molecola biologica, e l’efficacia ne consigliano un uso frequente e soprattutto nelle situazioni conclamate di immunodepressione neoplastica.

Documenti scientifici associati:

Per visualizzarne il contenuto è sufficiente collegarsi alla Banca Dati PubMed (clicca quì) riportando, con un semplice copia/incolla, il titolo della singola pubblicazione nell’apposita stringa di ricerca.
 

• Airoldi M, Pecchio F, Albanese F, Mastromatteo V, Gariboldi A, Di Costanzo G, Fazio M. [Urinary lysozyme, beta-2-microglobulin, and alpha-glucosidase during cisplatin therapy]. Boll Soc Ital Biol Sper. 1983 Mar 30;59(3):392-8.
• Alsabti E. The prognostic value of serum lysozyme activity in acute myelogenous leukemia. Med Pediatr Oncol. 1979;6(3):189-93.
• Altamar-Rios J. [Lysozyme in the treatment of juvenile laryngeal papillomatosis. A new concept in its etiopathogenesis]. An Otorrinolaringol Ibero Am. 1990;17(5):495-504.
• Armstrong TD, Clements VK, Ostrand-Rosenberg S. Class II-transfected tumor cells directly present endogenous antigen to CD4+ T cells in vitro and are APCs for tumor-encoded antigens in vivo. J Immunother. 1998 May;21(3):218-24.
• Arrese J, Paquet P, Claessens N, Pierard-Franchimont C, Pierard G. Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier. J Cutan Pathol. 2001 Mar;28(3):131-4.
• Astrom M, Bodin L, Hornsten P, Wahlin A, Tidefelt U. Evidence for a bimodal relation between serum lysozyme and prognosis in 232 patients with acute myeloid leukaemia. Eur J Haematol. 2003 Jan;70(1):26-33.
• Beeguer J, Casutt M, Stiksa E, Vassilakos P, Voegeli H. [Treatment of condylomata of the cervix uteri with local administration of lysozyme]. Schweiz Rundsch Med Prax. 1985 Nov 26;74(48):1337-9.
• Bianchi C. Is Fleming's lysozyme an analgesic agent? An experimental reappraisal of clinical data. Eur J Pharmacol. 1981 May 8;71(2-3):211-21.
• Bianchi C. Thrombocytopenia provoked by carrageenan in rabbits and the inhibitory effect of lysozyme. Agents Actions. 1982 Dec;12(5-6):657-61.
• Bjermer L, Back O, Roos G, Thunell M. Mast cells and lysozyme positive macrophages in bronchoalveolar lavage from patients with sarcoidosis. Valuable prognostic and activity marking parameters of disease? Acta Med Scand. 1986;220(2):161-6.
• Bosi A, Borsotti M, Ghelli P, Tozzi P, Bellesi G, Rossi Ferrini P. Serum angiotensin-I-converting enzyme and lysozyme levels in untreated and unsplenectomized patients with Hodgkin's disease. Acta Haematol. 1984;71(5):329-33.
• Bratlid D, Moe PJ. Serum lysozyme activity in children with acute leukemia. Eur J Pediatr. 1978 Apr 20;127(4):263-8.
• Bregant F, Ceschia V, Pacor S, Sava G. Reduction of MCa mammary carcinoma in mice fed with egg-white lysozyme.Pharmacol Res. 1990 Sep-Oct;22 Suppl 3:95-6.
• Bukharin 0V, Zykova LS, Tarasenko NF. Experimental and clinical study of the use of lysozyme in combination with chemotherapeutic agents. Antibiot Med Biotekhnol 1986; 31(12): 917-20.
• Burman LG, Lundblad G, Camner P, Fange R, Soder P. Lysozyme - an enzyme of both historical and curreni interest as a therapeutical agent. Lakartidningen 1991; 88 (44): 3665-8.
• Cavicchini S. [Use of high-dose lysozyme in the treatment of herpes zoster and flat warts]. Minerva Med. 1984 Mar 10;75(9-10):457-62.
• Cheuk W, Walford N, Lou J, Lee AK, Fung CF, Au KH, Mak LS, Chan JK. Primary histiocytic lymphoma of the central nervous system: a neoplasm frequently overshadowed by a prominent inflammatory component. Am J Surg Pathol. 2001 Nov;25(11):1372-9.
• Das S, Banerjee S, Gupta JD. Burman LG, Lundblad G, Camner P, Fange R, Lundborg M, Soder P. [Lysozyme--an enzyme of both historical and current interest as a therapeutical agent]. Lakartidningen. 1991 Oct 30;88(44):3665-8.
• De Vita O, Bondi A, Euse-Bi V, Bordi C. Simultaneous polypoid tumors of the stomach and duodenum with composite cell population (mucous, argyrophil, and lysozyme-containing cells): a case report. Am J Gastroenterol. 1984 Aug;79(8):606-10.
• Di Luzio NR. Lysozyme activity: an index of macrophage functional status. Front Biol. 1979;48:447-62.
• Dick W, Dopfer R. [Serum lysozyme level in children with acute leukemia and malignant diseases]. Padiatr Padol. 1985;20(1):25-32.
• Dick W, Schwandner G. [Clinical significance of lysozymes in colorectal tumors]. MMW Munch Med Wochenschr. 1982 Jun 25;124(25):619-20.
• Dick W. [Lysozyme: basic facts and diagnostic importance]. Fortschr Med. 1982 Jul 8;100(26):1230-4.
• Enzelsberger H, Metka M, Salzer H. [Effect of a parenteral ozone-oxygen mixture on the concentration of immunoglobulins (IgA, IgG, IgM), of vitamin A and lysozyme activity in patients with cervical cancer]. Geburtshilfe Frauenheilkd. 1987 Dec;47(12):343-5.
• Ferry JA, Srigley JR, Young RH. Granulocytic sarcoma of the testis: a report of two cases of a neoplasm prone to misinterpretation. Mod Pathol. 1997 Apr;10(4):320-5.
• Fois AM, Pourquier M, Bouisson AM. [Salivary pH and lysozyme during oropharyngeal radiotherapy]. J Biol Buccale. 1990 Sep;18(3):169-75.
• Fukawa K, Nishimura N, Irino O, Nakazato K, Taguchi A, Nitta K. Experimental studies on antitumor effects of lysozyme. Gan To Kagaku Ryoho 1982; 9 (5): 9 15-23.
• Fukuda T, Tominaga K, Abe M, Kusakabe T, Yamaki T, Hiraki H, Itoh S, Suzuki T. Characterization of a newly established human acinic cell adenocarcinoma cell line (HACC) originating from the salivary gland: morphological features and role of various growth factors on the growth of the HACC cell line. Pathol Int. 1998 Oct;48(10):791-9.
• Gorecka-Tisera A, Proctor JW, Yamamura Y, Harnaha J, Meinert K. Dose, route, and time dependence of serum lysozyme and antitumor activity following administration of glucan, Corynebacterium parvum, pyran, or lipopolysaccharide to mice. J Natl Cancer Inst. 1981 Oct;67(4):911-5.
• Inouye K. [The effects of lysozyme chloride on the immune response of patients with head and neck cancer]. Gan No Rinsho. 1987 Jun;33(6):627-32.
• Jung SM, Kuo TT, Wu JH, Shih LY. Granulocytic sarcoma presenting as a giant breast tumor in a pregnant woman: a case report. Changgeng Yi Xue Za Zhi. 1998 Mar;21(1):97-102.
• Karle H, Hansen NE, Plesner T. Neutrophil defect in multiple myeloma. Studies on intraneutrophilic lysozyme in multiple myeloma and malignant lymphoma. Scand J Haematol. 1976 Jul;17(1):62-70.
• Kemona H, Wysocka J, Prokopowicz J, Kiluk S. NBT test and serum lysozyme activity during remission of Hodgkin's disease. Acta Med Pol. 1986;27(3-4):163-9.
• Kim EH, Lee JC, Kim J, Son YO, Chung GH, Jang YS. Modulation of antigen-specific immune responses by the oral administration of a traditional medicine, bo-yang-hwan-o-tang. Immunopharmacol Immunotoxicol. 2002 Aug;24(3):423-40.
• Lieberman R, Fudenberg HH. Effects of BCG on lysozyme and “active” T cells in patients with malignant melanoma: a preliminary study. Clin Immunol Immunopathol. 1979 Feb;12(2):191-203.
• Liso V, Laricchia R. [Prognostic usefulness of lysozyme in acute myelomonocytic leukemias]. Minerva Med. 1983 Jun 30;74(27):1595-600.
• Mantur M, Matowicka-Karna J, Darewicz B, Kemona H, Dymicka-Piekarska V, Prokopowicz J, Darewicz. Embolization and serum lysozyme activity in renal cancer. Neoplasma. 1998;45(3):148-50.
• Martynova VA, Tolkacheva TV, Abakumov EM, Golosova TV. [Immunoglobulin and lysozyme content in the intestines during correction of the dysbacteriosis of acute leukemia patients]. Vopr Onkol. 1981;27(7):39-43.
• Mendiondo O, Suit H, Fixler H. Lysozyme levels and macrophage content of tumor tissue in C3H mice bearing fibrosarcoma transplants treated by radiation and Corynebacterium parvum. Int J Radiat Oncol Biol Phys. 1978 Sep-Oct;4(9-10):829-34.
• Meurman JH, Laine P, Keinanen S, Pyrhonen S, Teerenhovi L, Lindqvist C. Five-year follow-up of saliva in patients treated for lymphomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Apr;83(4):447-52.
• Nawrocka E. [Lysozyme in good health and in disease]. Pediatr Pol. 1978 Nov;53(11):1321-5.
• Neretto G, Agricola R, Giovanelli E, Poccardi G, Pellerito R, Furno F, Martinetto P, Pellegrino S, Daglio C, Tondolo M. [Evaluation of the serum lysozyme level as a further parameter for predicting hematological tolerance in patients treated with cytostatic chemotherapy. Study of 134 cases]. Recenti Prog Med. 1980 Oct;69(4):431-57.
• Neretto G, Giovanelli E, Agricola R, Pellegrino S, Bruno F, Mangione M, Furno F. [Lysozyme and cytostatic therapy]. Clin Ter. 1978 Dec 15;87(5):465-73.

• Pacor S, Giacomello E, Bergamo A, Clerici K, Zacchigna M, Boccu E, Sava G. Antimestatic action and lymphocyte activation by the modified lysozyme mPEG-Lyso in mice with Mca mammary carcinoma. Anticancer Res 1996; 16 (5A): 2559-64.
• Pajari U, Poikonen K, Larmas M, Lanning M. Salivary immunoglobulins, lysozyme, pH, and microbial counts in children receiving anti-neoplastic therapy. Scand J Dent Res. 1989 Apr;97(2):171-7.
• Pellerito R, Agricola R, Giovanelli E, Neretto G. [Blood lysozyme level and bone marrow granulocyte reserve]. Arch Sci Med (Torino). 1978 Oct-Dec;135(4):485-92.
• Proctor VA, Cunningham FE. The chemistry of lysozyme and its use as a food preservative and a pharmaceutical. Crit Rev Food Sci Nutr. 1988;26(4):359-95.
• Prokopowicz J, Merkiel K, Korenkiewicz A, Kiluk S. Serum lysozyme activity in patients with breast cancer treated by mastectomy and radiation. Neoplasma. 1984;31(4):491-6.
• Qi L, Rojas JM, Ostrand-Rosenberg S. Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo. J Immunol. 2000 Nov 15;165(10):5451-61.
• Sakai M, Okada M, Maruyama S, Yoshida S, Yamashita T, Takahashi K. [Combination chemotherapy with bleomycin ointment and lysozyme ointment against mouse WHT squamous cell carcinoma]. Gan To Kagaku Ryoho. 1990 Jan;17(1):103-7.
• Sava G, Benetti A, Ceschia V, Pacor S. Lysozyme and cancer: role of exogenous lysozyme as anticancer agent. Anticancer Res 1989; 9 (3): 583-91.
• Sava G, Ceschia V, Pacor S, Zorzet S, Perissin L. Antineoplastic action of egg-white lysozyme on the growth of MCa mammary carcinoma and TLX5 lymphoma in the CBA mouse. Methods Find Exp Clin Pharmacol. 1989 Nov;11(11):683-9.
• Sava G, Ceschia V, Pacor S. Mechanism of the antineoplastic action of lysozyme: evidence for host mediated effects. Anticancer Res 1989; 9 (4): 1175-80.
• Sava G, Ceschia V, Zabucchi G. Evidence for host-mediated antitumor effects of lysozyme in mice bearing the MCa mammary carcinoma. Eur J Cancer Clin Oncol. 1988 Nov;24(11):1737-43.
• Sava G, Pacor S, Dasic G, Bergamo A. Lysozyme stimulates lymphocyte response to ConA and IL-2 and potentiates 5-fluorouracil action on advanced carcinomas.Anticancer Res. 1995 Sep-Oct;15(5B):1883-8.
• Sava G, Pacor S, Nardon E, Dobrina A. Effects of endotoxin in mice bearing solid metastasizing tumors and treated with lysozyme hydrochloride. J Chemother. 1992 Aug;4(4):228-34.
• Sava G, Perissin L, Zorzet S, Callerio C. Antineoplastic effects of egg-white lysozyme in mice bearing solid metastasizing tumors. Anticancer Res. 1986 Mar-Apr;6(2):183-6.
• Sava G, Perissin L, Zorzet S. Antimetastatic action of orally administered lysozyme in mice bearing Lewis lung carcinoma. Clin Exp Metastasis. 1988 May-Jun;6(3):245-53.
• Sava G, Pharmacological aspects and therapeutic applications of lysozymes. Exs 1996; 75: 433-49.
• Sava G, Reduction of B16 melanoma metastases by oral administration of egg-white lysozyme. Cancer Chemother Pharmacol. 1989;25(3):221-2.
• Schirrmacher V, Bai L, Umansky V, Yu L, Xing Y, Qian Z. Newcastle disease virus activates macrophages for anti-tumor activity. Int J Oncol. 2000 Feb;16(2):363-73.
• Shugars DC, Watkins CA, Cowen HJ. Salivary concentration of secretory leukocyte protease inhibitor, an antimicrobial protein, is decreased with advanced age. Gerontology. 2001 Sep-Oct;47(5):246-53.
• Talageri VR, Seshadri KN, Advani SH. II-Evaluation of the prognostic value of the plasma lysozyme levels in leukaemia patients during therapy. Indian J Cancer. 1981 Dec;18(4):262-7.
• Tsuboi Y. [Evaluation on the clinical effect of lysozyme chloride in radiotherapy]. Rinsho Hoshasen. 1982 Oct;27(11):1271-4.
• Vacca A, Campobasso N, Iodice G, Ronco M, Dammacco F. Cyclic lysozyme administration as a tool for immunopotentiation in patients with multiple myeloma. Chemioterapia. 1985 Apr;4(2):147-55.
• Velardi A, Spinozzi F, Rambotti P, Tabilio A, Losito A, Zampi I, Cernetti C, Martelli MF, Grignani F, Davis S. The in vivo effect of thymic factor (thymostimulin) administration on circulating immune complexes and serum lysozyme levels in untreated Hodgkin's disease patients. J Clin Oncol. 1983 Feb;1(2):117-25.
• Veremeenko KN, Opanashchenko GA, Karpenko GF, Raiko IE. [Use of terrilytin combined with lysozyme in the treatment of postoperative wounds in patients with laryngeal cancer]. Vestn Otorinolaringol. 1985 Nov-Dec;(6):65-9.
• Warren JS, Rinehart JJ, Zwilling BS, Neidhart JA. Lysozyme enhancement of tumor cell immunoprotection in a murine fibrosarcoma. Cancer Res. 1981 May;41(5):1642.
• Yamaoka K, Yoshioka T. [Effects of lysozyme chloride on immune responses of patients with uterine cervical cancer]. Gan To Kagaku Ryoho. 1983 Aug;10(8):1803-9.